Get started
GT Biopharma, Inc.GT Biopharma, Inc.GT Biopharma, Inc.

GT Biopharma, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Technicals

GTBP chart

Key stats

Market capitalization
‪5.38 M‬USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−5.57USD
Net income
‪−7.60 M‬USD
Revenue
—
Shares float
‪1.24 M‬
Beta (1Y)
1.68

About GT Biopharma, Inc.

Sector
Health Technology
CEO
Michael Breen
Headquarters
Brisbane
Website
gtbiopharma.com
Employees (FY)
2
Founded
1965
ISIN
US36254L3087
FIGI
BBG000DHJ738
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The TriKE platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). Its product, GTB-3550, is initially developed for the treatment of AML and MDS, and other CD33+ hematologic cancers. GT Biopharma has worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology. The company was founded in 1965 and is headquartered in Brisbane, CA.

Financials

Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

Ideas

See all ideas 

News

Keep reading

Technicals

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Stock brokers

Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of GTBP is 3.80 USD — it has decreased by 2.56% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange GT Biopharma, Inc. stocks are traded under the ticker GTBP.
GT Biopharma, Inc. is going to release the next earnings report on May 13, 2024. Keep track of upcoming events with our Earnings Calendar.
GTBP earnings for the last quarter are −1.65 USD whereas the estimation was −3.00 USD which accounts for 44.98% surprise. Estimated earnings for the next quarter are −2.55 USD. See more details about GT Biopharma, Inc. earnings.
Yes, you can track GT Biopharma, Inc. financials in yearly and quarterly reports right on TradingView.
Like other stocks, GTBP shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GT Biopharma, Inc. stock right from TradingView charts — choose your broker and connect to your account.
GTBP reached its all-time high on Mar 28, 2016 with the price of 146 818.04 USD, and its all-time low was 3.52 USD and was reached on Feb 14, 2024.
See other stocks reaching their highest and lowest prices.
As of Apr 16, 2024, the company has 2.00 employees. See our rating of the largest employees — is GT Biopharma, Inc. on this list?